gennova-biopharmaceuticals-limitedgennova-biopharmaceuticals-limited
  • Home
    • Home
    • Contact Us
    • Careers
  • About Us
    • About Us
    • Company Profile
    • Our Values
    • Board of Directors
    • Our Strengths
    • PDL
    • Our Collaborations
  • Media
    • Media
    • News Coverage
    • Gallery
    • Employee Moments
  • Products
    • Products
    • Elaxim®
    • GEMCOVAC®-OM
    • Hamsyl®
    • Hamsyl® Junior
    • PEGEX®
    • TENECTASE®
    • Vintor®
    • Xgrast®
  • Publications
  • Abhyudaya
  • Transforming Healthcare
    • Transforming Healthcare
    • Global Health Initiative
      • Global Health Initiative
      • PHT
Gennova Logo Gennova Logo
  • Home
    • Home
    • Contact Us
    • Careers
  • About Us
    • About Us
    • Company Profile
    • Our Values
    • Board of Directors
    • Our Strengths
    • PDL
    • Our Collaborations
  • Media
    • Media
    • News Coverage
    • Gallery
    • Employee Moments
  • Products
    • Products
    • Elaxim®
    • GEMCOVAC®-OM
    • Hamsyl®
    • Hamsyl® Junior
    • PEGEX®
    • TENECTASE®
    • Vintor®
    • Xgrast®
  • Publications
  • Abhyudaya
  • Transforming Healthcare
    • Transforming Healthcare
    • Global Health Initiative
      • Global Health Initiative
      • PHT
 
Research Articles

Elucidation of molecular mechanism of stability of the heme-regulated eIF2α kinase upon binding of its ligand, hemin in its catalytic kinase domain.

  • admin
  • April 9, 2020

J Biomol Struct Dyn. 2018 Aug;36(11):2845-2861. doi: 10.1080/07391102.2017.1368417. Epub 2017 Sep 12. PubMed PMID: 28814160.

https://www.ncbi.nlm.nih.gov/pubmed/?term=28814160

Share
Gennova Logo

About Gennova

Board of Directors
Research Collaborations
Corporate Governance
Internships
Careers
Press Kit
Contact Us

Products

Elaxim®
GEMCOVAC®-OM
Hamsyl®
Hamsyl® Junior

PEGEX®
TENECTASE®
Vintor®
Xgrast®

©2006-2025 Gennova Biopharmaceuticals Limited. All rights reserved.